SCHEMBL24330488

SCHEMBL24330488

Cc1cccc(CC(C)(C)C)c1-c1nc(N)nc(Cl)c1C

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 6/20 0.34
▸ ADORA2A P29274 4/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ TNF P01375 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ NOD1 Q9Y239 1/20 0.33
▸ ADORA1 P30542 2/20 0.32
▸ DHFR P00374 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ KDR P35968 1/20 0.31
▸ HSP90B1 P14625 1/20 0.31
▸ TRAP1 Q12931 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ HEXA P06865 1/20 0.31
▸ HEXB P07686 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29515202 1.00 HSP90AA1 (0.34) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL24330396 0.82 HSP90AA1 (0.42) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL29515320 0.82 HSP90AA1 (0.42) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL29515213 0.81 GABRA1 (0.36) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL24331524 0.81 GABRA1 (0.36) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL24330556 0.79 NOS3 (0.35) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL29515019 0.79 NOS3 (0.35) HSP90AA1ADORA2ANPC1JAK2TNF
SCHEMBL24331390 0.78 ADORA3 (0.31) —
SCHEMBL29515114 0.78 ADORA3 (0.31) —
SCHEMBL24330533 0.78 HSP90AA1 (0.35) HSP90AA1ADORA2ANPC1JAK2TNF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374038-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-11-23 — — US disclosed
US-20230374038-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2023-11-23 — — US disclosed
WO-2023196429-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-12 — — WO disclosed
WO-2022076620-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374038-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B HSP90AA1 1237/4885ADORA2A 1783/4885NPC1 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback